NEYROS
The research company, carrying out studies and development of new pharmaceutical drug candidate for treatment of neurodegenerative disorders and cerebrovascular ischemia.
NEYROS projects are aimed at creating new pharmaceutical candidates for the treatment of Parkinson's disease, age-related dementia, Alzheimer's disease, as well as anti-ischemic drugs for increasing the duration of the "golden hour" during stroke.
Researchers are using an advanced brain imaging method called MEG to understand why Parkinson’s drug levodopa doesn’t work equally well for everyone. By mapping patients’ brain signals before and after taking the drug, they discovered that it sometimes activates the wrong brain regions, dampening its helpful effects. This breakthrough could pave the way for personalized treatment strategies, ensuring patients receive medications that target the right areas of their brain more effectively.
